title: [A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].
abstract: The patient, a male in his 70s, was referred to this hospital by his neighborhood doctor with what was said to be impaired hepatic function. Detailed examinations revealed a circumferential ascending colon cancer, diffuse hepatic metastases scattered over both liver lobes, and lymph node metastases in the left axilla. With the primary lesion-induced symptoms of stenosis controllable, the patient began systemic chemotherapy by mFOLFOX6 without a resection of the primary lesion. After completing a 10-course treatment, the patient underwent surgery to resect the primary lesion in preparation for bevacizumab treatment. In the postoperative systemic chemotherapy, FOLFIRI and mFOLFOX6 were administered concomitantly with bevacizumab. After a total of 19 courses, the patient's systemic condition gradually deteriorated. He eventually died of cancer one year and seven months after diagnosis of the primary lesion or one year and one month subsequent to the resection of the primary lesion. No consensus has been reached on the necessity to resect the primary lesion in patients with advanced colorectal cancer who also have unresectable distal metastases. Systemic chemotherapy, nevertheless, can provide tumor control on both primary and metastatic lesions and could become a treatment option in the future.
authors.affiliation: Department of Coloproctological Surgery, Juntendo University.
authors.forename: Kiichi
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Tashiro
authors.forename: Kiichi
authors.initials: K
authors.lastname: Nagayasu
authors.forename: Kouichiro
authors.initials: K
authors.lastname: Niwa
authors.forename: Seigo
authors.initials: S
authors.lastname: Ono
authors.forename: Shun
authors.initials: S
authors.lastname: Ishiyama
authors.forename: Masaki
authors.initials: M
authors.lastname: Hata
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Komiyama
authors.forename: Makoto
authors.initials: M
authors.lastname: Takahashi
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Yaginuma
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kojima
authors.forename: Michitoshi
authors.initials: M
authors.lastname: Goto
authors.forename: Masanobu
authors.initials: M
authors.lastname: Tanaka
authors.forename: Hironobu
authors.initials: H
authors.lastname: Sengoku
authors.forename: Atsushi
authors.initials: A
authors.lastname: Okuzawa
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Tomiki
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Sakamoto
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003113:Colonoscopy; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin